Uninsured with Rectal Cancer are More Likely to Die

Insurance makes a difference for people with rectal cancer.

Rectal cancer patients without insurance or covered by Medicaid are almost twice as likely to die within five years as those privately insured.

Not only are they diagnosed at a later stage, but fewer receive recommended treatments at every stage.

More than half of the difference between patients with private insurance and those without was due to differences in how early they were diagnosed and whether or not they got standard treatment.

Researchers looked at information from the National Cancer Data Base, a national hospital-based cancer registry, to study insurance and other factors related to survival among 19,154 rectal cancer patients aged 18 to 64 years old.

They analyzed the impact of  insurance, age, sex, race and ethnicity, neighborhood education and income levels, cancer treatment facility type, stage, pathology features, and treatment on survival at five years.

Rectal cancer patients were diagnosed between 1998 and 2002, and their progress was followed until 2007.

Results

Differences in standard treatment

Writing in an early online edition of Cancer, Anthony S. Robbins, MD, PhD and his team in the Department of Surveillance and Health Policy Research at the American Cancer Society said,

Our main finding that most of the excess mortality seen among Medicaid-insured and uninsured patients was explained by 2 modifiable factors (stage and treatment) suggests that improving insurance coverage and reducing cost-related barriers to primary care, CRC screening, and high-quality treatment would have a major impact on CRC survival disparities.

SOURCE: Robbins et al., Insurance status and survival disparities among nonelderly rectal cancer patients in the National Cancer Data Base, Cancer, Early View, June 2010.

Bookmark and Share

This news article was originally posted on July 22nd, 2010 and was accurate at the time of publication. Since then, information may have changed or links may now be outdated. Please call our Answer Line 1-877-427-2111 for the latest information, or talk to your doctor before making any medical decisions.

Posted by Kate Murphy on July 22nd, 2010
Tags: disparities, prognosis, rectal cancer

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Register to receive our free e-newsletter

Get monthly updates on colorectal cancer treatment options, research news and advocacy opportunities. We promise to not bombard you with email - just enough to keep you informed on how to fight colorectal cancer.

First Name

Last Name

Email

Donate

Support C3 and the Lisa Fund for Research

Donate to C3

Donate to The Lisa Fund

Learn more about the Lisa Fund

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe